Nomogram for predicting the benefit of neoadjuvant chemoradiotherapy for patients with esophageal cancer: A SEER-medicare analysis

Cancer

Volumn 120, Issue 4, 2014, Pages 492-498

  Eil, Robert ^a   Diggs, Brian S ^a   Wang, Samuel J ^b   Dolan, James P ^a   Hunter, John G ^a   Thomas, Charles R ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

chemoradiotherapy; esophageal cancer; neoadjuvant; nomogram; predictive tool

Indexed keywords

CHEMORADIOTHERAPY; ESOPHAGEAL CANCER; NEOADJUVANT; NOMOGRAM; PREDICTIVE TOOL;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MEDICARE; MIDDLE AGED; NEOADJUVANT THERAPY; NOMOGRAMS; PROGNOSIS; SEER PROGRAM; UNITED STATES;

EID: 84893727923     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28447     Document Type: Article

References (24)

1. Holmes RS, Vaughan TL,. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol. 2007; 17: 2-9. (Pubitemid 44918357)
2. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62: 220-241.
3. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366: 2074-2084.
4. Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005; 23: 4330-4337. (Pubitemid 46207006)
5. National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program. SEER Stat Database: Incidence-SEER 17 Regs Public Use, Nov 2005 Sub (1973-2003 varying). Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; 2006.
6. National Cancer Institute. Surveillance Epidemiology, and End Results (SEER)-Medicare. SEER-Medicare Linked Database. healthservices.cancer.gov/ seermedicare. Accessed March 12, 2012.
7. Harrell FE,. Regression Modeling Strategies. New York, NY: Springer-Verlag; 2010.
8. Austin PC,. The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Making. 2009; 29: 661-677.
9. van Vliet EP, Heijenbrok-Kal MH, Hunink MG, et al. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer. 2008; 98: 547-557. (Pubitemid 351214529)
10. Wang SJ, Lemieux A, Kalpathy-Cramer J, et al. Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol. 2011; 29: 4627-4632.
11. Akaike H,. A new look at the statistical model identification. IEEE Trans Autom Control 1974; 19: 716-723.
12. Swisher SG, Hofstetter W, Wu TT, et al. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005; 241: 810-817; discussion 817-820.
13. Donahue JM, Nichols FC, Li Z, et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg. 2009; 87: 392-398.
14. Brucher BL, Becker K, Lordick F, et al. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer. 2006; 106: 2119-2126.
15. Gaur P, Sepesi B, Hofstetter WL, et al. A clinical nomogram predicting pathologic lymph node involvement in esophageal cancer patients. Ann Surg. 2010; 252: 611-617.
16. Suzuki A, Xiao L, Hayashi Y, et al. Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology. 2012; 82: 108-113.
17. Streyerberg EW, Neville BA, Koppert LB, et al. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol. 2008; 24: 4277-4283.
18. Grotenhuis BA, van Hagen P, Reitsma JB, et al. Validation of a nomogram predicting complications after esophagectomy for cancer. Ann Thorac Surg. 2010; 90: 920-925.
19. Rice TW, Rusch VW, Apperson-Hansen C, et al. Worldwide esophageal cancer collaboration. Dis Esophagus. 2009; 22: 1-8.
20. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005; 103: 1347-1355. (Pubitemid 40410728)
21. Kalha I, Kaw M, Fukami N, et al. The accuracy of endoscopic ultrasound for restaging esophageal carcinoma after chemoradiation therapy. Cancer. 2004; 101: 940-947. (Pubitemid 39100426)
22. Ajani JA, Correa AM, Hofstetter WL, et al. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2012; 23: 2638-2642.
23. Omloo JM, van Heijl M, Hoekstra OS, et al. FDG-PET parameters as prognostic factor in esophageal cancer patients: a review. Ann Surg Oncol. 2011; 18: 3338-3352.
24. Fockens P, Van den Brande JH, van Dullemen HM, van Lanschot JJ, Tytgat GN,. Endosonographic T-staging of esophageal carcinoma: a learning curve. Gastrointest Endosc. 1996; 44: 58-62. (Pubitemid 26268660)